NFKB1 and familial pancreatic carcinoma: Recently, it was reported that oxaliplatin‐induced NF‐κB activation in a pancreatic cancer cell line and that this may be linked with cancer drug resistance.27 We hypothesized that oxaliplatin may regulate immunosuppressive MDSCs through the positive or negative modulation of signaling pathways, such as the NF‐κB pathway.